(Rac) -Zevaquenabant

(Rac) -Zevaquenabant ((Rac) -MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R) /iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac) -Zevaquenabant is potential for the research of liver fibrosis[1].

Product Specifications

CAS Number

[1610420-28-4]

Product Name Alternative

(Rac) -MRI-1867

UNSPSC

12352005

Target

Cannabinoid Receptor; NO Synthase

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/rac-zevaquenabant.html

Purity

99.20

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=S(/N=C(N1N=C(C2=CC=C(Cl)C=C2)C(C3=CC=CC=C3)C1)/N=C(N)/C)(C4=CC=C(C(F)(F)F)C=C4)=O

Molecular Formula

C25H21ClF3N5O2S

Molecular Weight

547.98

References & Citations

[1]Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB 1 R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.